Jump to content

FDA revamps how it reviews cancer drugs


Recommended Posts

FDA revamps how it reviews cancer drugs

New process aims to speed evaluation of productsThe Associated Press

Updated: 6:48 p.m. ET July 15, 2004

WASHINGTON - The Food and Drug Administration is revamping how it reviews drugs to treat, diagnose and prevent cancer, hoping to speed evaluation of the products.

Under the restructuring, a new Office of Oncology Drug Products will oversee both traditional chemotherapies and biologically based treatments, as well as imaging agents to diagnose cancer and the new field of cancer prevention drugs.

The hope is that having everything under one roof not only could speed evaluation, but ensure they’re all held to the same scientific standards.

“We are committed to creating the most effective and efficient review process possible to ensure life-saving treatments are made available to cancer patients,” said Health and Human Services Secretary Tommy Thompson, who will announce the reorganization on Friday.

Officials couldn’t quantify how much faster evaluations could be made. Cancer treatments already get quick reviews within FDA; one was cleared in a record seven weeks.

© 2004 The Associated Press. All rights reserved.

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use. We have placed cookies on your device to help make this website better. You can adjust your cookie settings, otherwise we'll assume you're okay to continue.